Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for alendronate
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
The efficiency and safety of teriparatide versus alendronate for the treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials in China Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability
Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis.In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients (...) with only alendronate showed significantly decreased levels of BALP and CTx and increased levels of osteocalcin compared to the control group. The alendronate group also showed significant increases in the total body, total hip, lumbar spine and femoral neck BMDs at the end of study compared to the control group. In the curcumin + alendronate group, BALP and CTx levels decreased and osteocalcin levels increased significantly at the end of study compared to the control and alendronate groups. BMD indexes
Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women. Objective To investigate the relationship between geranylgeranyl pyrophosphate synthase (GGPPS) gene polymorphisms and bone response to alendronate in Chinese osteoporotic women.Methods A total of 639 postmenopausal women with osteoporosis or osteopenia were included and randomly received treatment of low dose (70 mg per two weeks (...) ) or standard dose (70 mg weekly) of alendronate for one year. The six tag single nucleotide polymorphisms of GGPPS gene were identified. Bone mineral density (BMD), serum cross-linked C-telopeptide of type I collagen (β-CTX), and total alkaline phosphatase (ALP) were measured before and after treatment. GGPPS gene polymorphisms and the changes of BMD and bone turnover markers after treatment were analyzed.Results rs10925503 polymorphism of GGPPS gene was correlated to serum β-CTX levels at baseline
Alendronate Top results for alendronate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alendronate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate (...) femoral fractures were adjudicated.Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids.To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects.Retrospective cohort study using a national database (N (...) = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred between January 2008 and December 2014.Alendronate vs no alendronate
Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday UTCAT3257, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday Clinical Question In patients being treated with oral (...) alendronate and wanting a dental implant, does taking a drug holiday decrease the likelihood of developing osteonecrosis of the jaw? Clinical Bottom Line Patients being treated with oral alendronate and in need of a dental implant should have their dentist discuss the discontinuation of their oral bisphosphonate with their prescribing physician before continuing with dentoalveolar surgical treatment. The amount of risk reduction seems to necessitate further investigation and therefore, one cannot provide
Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty Bone mineral density (BMD) loss around femoral implants, particularly in the proximal femur, is a common outcome after total hip arthroplasty. Previous studies reported the prevention of postsurgical decrease in BMD with the use of osteoporosis drug therapy. This randomized study evaluated the efficacy of alendronate and alfacalcidol for preserving BMD over a long-term follow-up.Sixty (...) consecutive patients with hip osteoarthritis who had undergone primary cementless total hip arthroplasty were randomly assigned to an alendronate (n = 20), alfacalcidol (n = 18), or control (n = 22) group. Periprosthetic BMD was measured using dual-energy X-ray absorptiometry at 1 week, 1 year, and the current follow-up (minimum 9 years after surgery). Changes in BMD are reported as mean percentages relative to the values at 1 week (baseline reference).All groups showed a significant decrease in the BMD
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. To determine the skeletal safety and efficacy of long term (≥10 years) alendronate use in patients with osteoporosis. Open register based cohort study containing two nested case control studies. Nationwide study of population of Denmark. 61 990 men and women aged 50-94 at the start of treatment, who had not previously taken alendronate, 1996 (...) -2007. Treatment with alendronate. Incident fracture of the subtrochanteric femur or femoral shaft (ST/FS) or the hip. Non-fracture controls from the cohort were matched to fracture cases by sex, year of birth, and year of initiation of alendronate treatment. Conditional logistic regression models were fitted to calculate odds ratios with and without adjustment for comorbidity and comedications. Sensitivity analyses investigated subsequent treatment with other drugs for osteoporosis. 1428
Alendronate USE OF ALENDRONIC ACID IN PREGNANCY 0344 892 0909 USE OF ALENDRONIC ACID IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Alendronic acid is a bisphosphonate licensed in adults for the treatment of postmenopausal osteoporosis (...) and for the prophylaxis of glucocorticoid-induced osteoporosis. As alendronic acid is incorporated into bone, the terminal half-life is long (up to 10 years). Fetal exposure could therefore occur in pregnant women with a history of alendronic acid use prior to conception. Animal studies have demonstrated that alendronic acid can be absorbed into the fetal skeleton and affect offspring incisor eruption. The available human exposure data are highly limited, consisting of a single prospective cohort study and case
Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening
Oral ulcers, a little known adverse effect of alendronate: review of the literature Oral ulcers, a little known adverse effect of alendronate: review of the literature Oral ulcers, a little known adverse effect of alendronate: review of the literature Kharazmi M, Sjoqvist K, Warfvinge G CRD summary The review concluded that alendronate was associated with development of oral ulcers as healing occurred when the drug was either withdrawn or administered correctly. Due to very limited evidence (...) and substantial risk of bias in the review process, the authors' conclusions cannot be considered reliable. Authors' objectives To review the published data on the relationship of mucosal ulcers in the oral cavity with the use of alendronate. Searching PubMed was searched for relevant published studies from 1966 to August 2010. There were no language restrictions. Limited search terms were reported. Reference lists of selected reports were searched. Study selection Studies that reported ulceration of the oral
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis The aim of this study was to perform a head-to-head comparison of efficacy and safety profile between 60 mg denosumab (Den) subcutaneously (SC) per 6 months (Q6M) and 70 mg alendronate (Aln) orally per week (QW) for postmenopausal women with low bone mineral density. We searched electronic databases comparing efficacy and safety of Den SC Q6M and Aln QW (...) heterogeneous randomised controlled trials (RCTs) involving 1942 women were identified. The results of review showed low evidence quality that supported the hypothesis the denosumab vs. alendronate could reduce risk of fracture [OR (95% CI) 1.42 (0.84 to 2.40), 11 more women per 1000 (from 4 fewer to 36 more), p = 0.19] but the moderate to high quality evidence suggesting treatment with 60 mg Den SC Q6M was more effective for postmenopausal women in increasing BMD [at distal radius (DR), total hip (TH
Proton pump inhibitor use and the antifracture efficacy of alendronate Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.Population-based, national (...) register-based, open cohort study of 38,088 new alendronate sodium users with a mean duration of follow-up of 3.5 years. We related risk of hip fracture to recent pharmacy records of refill of prescriptions for alendronate.For hip fractures, there was statistically significant interaction with alendronate for PPI use (P < .05). The treatment response associated with complete refill compliance to alendronate was a 39% risk reduction (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.52-0.71; P
Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw. 20950167 2010 12 21 2016 11 25 1533-4406 363 25 2010 Dec 16 The New England journal of medicine N. Engl. J. Med. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. 2473-4 10.1056/NEJMc1002684 Cheung Ada A Seeman Ego E eng Case Reports Letter 2010 10 16 United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 10T9CSU89I Teriparatide X1J18R4W8P Alendronate AIM IM N Engl J Med (...) . 2011 Mar 17;364(11):1081-2; author reply 1082 21410382 N Engl J Med. 2010 Dec 16;363(25):2458-9 20950165 Aged, 80 and over Alendronate adverse effects Bone Density Conservation Agents adverse effects therapeutic use Bone Regeneration drug effects Female Humans Jaw diagnostic imaging pathology Jaw Diseases chemically induced drug therapy Osteonecrosis chemically induced drug therapy Radiography Teriparatide therapeutic use 2010 10 19 6 0 2010 10 19 6 0 2010 12 22 6 0 ppublish 20950167 10.1056
Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patients also suggest benefits of bisphosphonates on vascular calcification; however, no study exists (...) in nondialysis patients with CKD.We conducted a randomized controlled trial to determine the effect of bisphosphonates on vascular calcification in patients with CKD.51 patients with CKD stages 3-4 were recruited from a hospital outpatient setting; 50 were treated with study medication.Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly.The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes
The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of risedronate compared with generic alendronate for the treatment of postmenopausal women with osteoporosis. The authors concluded that risedronate
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis Bone loss is often observed in patients with ulcerative colitis, particularly if they require glucocorticoids.To determine whether the bisphosphonate, alendronate, is safe and effective in preserving bone mass compared to the active vitamin D3, alfacalcidol, in ulcerative colitis patients receiving glucocorticoids.Thirty-nine patients with ulcerative colitis (...) and treated with glucocorticoids were randomized to receive alendronate (5 mg/day) or alfacalcidol (1 microg/day) daily for 12 months. Loss of bone mass was evaluated by bone mineral density, bone resorption by urinary N-telopeptide for type I collagen, and bone formation by serum bone alkaline phosphatase.Alendronate, but not alfacalcidol, significantly increased bone mineral density in the lumbar spine. Alendronate decreased serum bone alkaline phosphatase levels, but alfacalcidol did not. Urinary N